GEMINA LABS LTD (8I7) - Total Liabilities
Based on the latest financial reports, GEMINA LABS LTD (8I7) has total liabilities worth €6.25 Million EUR (≈ $7.31 Million USD) as of October 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore 8I7 net asset momentum to track the company's year-over-year net asset growth rate.
GEMINA LABS LTD - Total Liabilities Trend (2022–2025)
This chart illustrates how GEMINA LABS LTD's total liabilities have evolved over time, based on quarterly financial data. See how much free cash does GEMINA LABS LTD generate to measure how efficiently the company converts operating cash flow to free cash.
GEMINA LABS LTD Competitors by Total Liabilities
The table below lists competitors of GEMINA LABS LTD ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Tanah Laut Tbk
JK:INDX
|
Indonesia | Rp21.99 Billion |
|
Rubico Inc. Common Stock
NASDAQ:RUBI
|
USA | $88.27 Million |
|
Montanaro UK Smaller Companies Investment Trust PLC
LSE:MTU
|
UK | GBX13.84 Million |
|
CanadaBis Capital Inc
V:CANB
|
Canada | CA$16.64 Million |
|
Oakridge International Ltd
AU:OAK
|
Australia | AU$1.04 Million |
|
Flexituff Ventures International Limited
NSE:FLEXITUFF
|
India | Rs4.67 Billion |
|
Ngenic AB
ST:NGENIC
|
Sweden | Skr65.29 Million |
|
CBEYOND
F:C5B
|
Germany | €400.03K |
Liability Composition Analysis (2022–2025)
This chart breaks down GEMINA LABS LTD's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see GEMINA LABS LTD (8I7) total market value.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.01 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -1.22 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 5.63 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how GEMINA LABS LTD's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for GEMINA LABS LTD (2022–2025)
The table below shows the annual total liabilities of GEMINA LABS LTD from 2022 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-01-31 | €5.87 Million ≈ $6.87 Million |
+93.11% |
| 2024-01-31 | €3.04 Million ≈ $3.56 Million |
+56.23% |
| 2023-01-31 | €1.95 Million ≈ $2.28 Million |
+309.06% |
| 2022-01-31 | €475.92K ≈ $556.40K |
-- |
About GEMINA LABS LTD
Gemina Laboratories Ltd., a biotechnology company, engages in the research, development, and commercialization of in-vitro diagnostics in Canada. The company's products include LEGIO X COVID-19, a COVID-19 rapid antigen test; and LEGIO X Influenza AB, an influenza AB multiplex lateral flow test. It also develops respiratory syncytial virus and tuberculosis. Gemina Laboratories Ltd. was incorporat… Read more